Date of Graduation

5-2014

Document Type

Dissertation (PhD)

Program Affiliation

Cancer Biology

Degree Name

Doctor of Philosophy (PhD)

Advisor/Committee Chair

Mong-Hong Lee

Committee Member

Min Gyu Lee

Committee Member

Hui-Kuan Lin

Committee Member

Dos Sarbassov

Committee Member

Sai-Ching Jim Yeung

Abstract

Epidemiological studies have identified that type 2 diabetes mellitus (DM2) is a significant risk factor for carcinogenesis and cancer death, including breast cancer. Our previous finding in patients showed that anti-insulin resistance treatments are associated with improved HER2+ breast cancer survival of diabetic women. However, there were no transgenic mouse models to study the correlation and explain the detailed mechanism. We generated a mouse model of HER2+ breast cancer with DM2 by crossing leptin receptor point mutation (Lepr db/+) and MMTV-ErbB2 (neu) mice. The MMTV-ErbB2/Lepr db/db mice had a poor survival rate compared with MMTV-ErbB2/Lepr +/+ mice, and the log rank test of the Kaplan-Meier analysis showed that they were significantly different (P = 0.0004). In addition, we evaluated the impact of different anti-diabetic medications on cancer-specific survival. MMTV-ErbB2/Lepr db/db mice administrated with metformin or rosiglitazone showed improved overall survival, cumulative tumor incidence, and reduced tumor progression. Anti-insulin resistance treatments can also reverse the Warburg effect by reducing lactate/pyruvate ratio through 13C-pyruvate imaging. Cell lines isolated from MMTV-ErbB2/Lepr db/db mice also showed reduced levels of both oxygen consumption and lactate production upon metformin treatment. Metformin treatment not only inhibited proliferation and induced apoptosis in Human HER2+ breast cancer cell lines, but also repressed c-MYC mRNA expression, increased proteasome-dependent degradation, and reduced the downstream key glycolysis enzyme PKM2. Moreover, anti-insulin resistance treatments dramatically change the microenvironment by reducing serum insulin levels and this systematic effect attenuated the mTOR/AKT signaling pathway in tumor samples from MMTV-ErbB2/Lepr db/db mice. Anti-insulin resistance treatments also affected adipokine expression profiles and may reveal potential targets for further research. In conclusion, our results indicate the therapeutic effect of anti-insulin resistance treatments on breast cancer metabolism and this animal model also shed the light on the clinical implications of anti-insulin resistance treatments on HER2+ breast cancer patients accompanied with the DM2 condition.

Keywords

HER2, breast cancer, DM2, diabetes treatment, metformin, rosiglitazone, metabolism, insulin resistant

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.